# BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

> **NCT04136470** · — · UNKNOWN · sponsor: **Ardigen** · enrollment: 130 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Microbiome
- Metagenome
- Immunotherapy
- Melanoma

## Interventions

- **BIOLOGICAL:** Collection of stool, blood (PBMC) and biopsy (FFPE)

## Key facts

- **NCT ID:** NCT04136470
- **Lead sponsor:** Ardigen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-01
- **Primary completion:** 2020-09-30
- **Final completion:** 2021-03-31
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2020-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04136470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04136470, "BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04136470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*